Introduction {#sec1}
============

Colorectal cancer (CRC) is the second and third most commonly diagnosed cancer in males and females, respectively, with over 1.2 million new cancer cases and 608,700 deaths estimated to have occurred in 2008 \[[@cit0001]\]. Despite a slight decrease in its incidence and mortality during the past decades in China, CRC remains the fifth most common cancer, with an age standardized rate of 215.7 and 160.6 per 100,000 among men and women, respectively \[[@cit0002]\]. Generally, CRC is considered a disease of the older population with more than 90% patients diagnosed beyond 55 years \[[@cit0003]\]. In China, the age standardized rate of patients under 30 years of age and 30--44 years of age is 1.1 and 13.0 per 100,000, which is significantly lower than that of patients aged 60 to 74 years (90.9 per 100,000) \[[@cit0002]\]. In recent years, a relative increase in the number of young patients diagnosed with CRC in the last decade has been reported in many countries \[[@cit0004]\]. Previous research has shown that young CRC patients have many unique characteristics with a relatively poorer prognosis, but these studies include all histologic types \[[@cit0005]--[@cit0009]\]. Although adenocarcinoma is the most common histologic subtype of CRC, mucinous and signet ring cell subtypes of adenocarcinoma are seen more frequently in young patients \[[@cit0010]\]. Additionally, Tawadros \[[@cit0011]\] reported that rectal cancer patients under 40 years of age were 3.6 times more likely to have signet cell histology. However, to our best knowledge, little information is available regarding the survival and prognostic factors of young patients (≤ 40 years) with mucinous adenocarcinoma (MAC) and signet-ring cell carcinoma (SRC). We thus conducted this retrospective study to specifically assess the long-term survival and prognostic factors for patients with MAC and SRC in this age group.

Material and methods {#sec2}
====================

Patients {#sec2.1}
--------

The medical records of the patients who underwent surgical resection at the Cancer Hospital of China Medical University from 2006 to 2013 with a diagnosis of colorectal MAC and SRC were retrieved from our department. A total of 90 patients with histopathologically confirmed colorectal MAC and SRC were identified with an age ≤ 40 years and were included in the present analysis.

Clinical variables and definitions {#sec2.2}
----------------------------------

Data including gender, age at diagnosis, date of diagnosis, tumor site, pathological diagnosis, tumor stage at the time of diagnosis, adjuvant chemotherapy, cycles of adjuvant chemotherapy, preoperative carcinoembryonic antigen (CEA) levels, and pathologic features (T stage, N stage, M stage, lymphovascular and perineural invasion) were obtained by reviewing the medical records. All tumors were staged according to the TNM staging system of the American Joint Committee on Cancer (7^th^ version, 2009). The tumor site was classified as colon or rectum. The cut-off CEA concentration was 5.0 ng/day, which in our laboratory is the CEA concentration considered abnormal. In this study, patients ≤ 40 years at diagnosis were referred to as young patients; the decision of 40 years as a cut off was based on previously published results \[[@cit0011]--[@cit0014]\]. Written informed consent was obtained from all patients and the study procedures were approved by the Ethical Committee of Cancer Hospital of China Medical University.

Follow-up {#sec2.3}
---------

Patients were followed at 3-month intervals for 2 years, at 6-month intervals for the next 3 years, and annually thereafter. The date of the last follow-up was March 2016, which was mainly made with telephone calls. Recurrence was determined by clinical and radiologic examination or histologic confirmation. The main pattern of recurrence was recorded as the first site of detectable failure during the follow-up period. Disease-free survival (DFS) was the time from the surgery to the local or distant failure. Overall survival (OS) was calculated from surgery to death induced by all causes or end of follow-up.

Statistical analysis {#sec2.4}
--------------------

Survival analysis was conducted using the Kaplan-Meier method. The comparison of the survival curves was performed by the log-rank test. A multivariable Cox-regression analysis was performed to identify predictive factors of overall survival. Every variable was analyzed by univariate analysis, in order to cover all potentially important predictors, then variables with *p* ≤ 0.10 in univariate analysis were included in the multivariable analysis. This level was chosen to incorporate all potentially important predictor variables in the final modeling process. All sets of variables were analyzed: gender, pathologic T stage, N stage, M stage, AJCC stage, adjuvant chemotherapy, cycles of adjuvant chemotherapy, tumor size, tumor location, lymphovascular invasion, perineural invasion, preoperative CEA levels, histological subtype (MAC versus SRC) and surgical types (radical versus palliative). Statistical analysis was performed using SPSS 16.0 software (SPSS Inc., Chicago, IL, United States). *P* \< 0.05 was considered statistically significant.

Results {#sec3}
=======

Patient characteristics {#sec3.1}
-----------------------

The clinical and pathological characteristics of 90 patients (male-to-female ratio: 2.1 : 1) are summarized in [Table I](#t0001){ref-type="table"}. The median age was 36 (20--40) years, and median follow-up time was 36.5 (3--109) months. The treatment intention was radical for 65 (72.2%) patients. The mean preoperative CEA level was 18.5 U/ml (range: 0.2--279 U/ml). A total of 83 patients received adjuvant chemotherapy after surgery excepting for 7 patients, and 77 patients received more than six cycles of adjuvant chemotherapy ([Table I](#t0001){ref-type="table"}). The median total number of lymph nodes harvested was 17 (range: 2--33).The number of patients with more than 12 lymph nodes was 76 (84%, [Table I](#t0001){ref-type="table"}).

###### 

Clinicopathologic characteristics of 90 young patients with MAC and SRC

  Variable                           Value
  ---------------------------------- -----------------
  Age, median (range) \[years\]      36 (20--40)
  Gender, *n*:                       
   Male                              69
   Female                            21
  Primary tumor location, *n*:       
   Colon                             48
   Rectum                            42
  Histologic types, *n*:             
   MAC                               69
   SRC                               21
  Adjuvant CT, *n*:                  
   Yes                               83
   No                                7
  Cycles of adjuvant CT, *n*:        
   ≥ 6                               77
   \< 6                              13
  Tumor size \[cm\]:                 
   ≥ 5                               45
   \< 5                              45
  Surgical type, *n*:                
   Radical                           65
   Palliative                        25
  T stage, *n*:                      
   T1/T2                             4
   T3/T4                             86
  N stage, *n*:                      
   N0                                23
   N1                                30
   N2                                37
  Metastasis, *n*:                   
   No                                69
   Yes                               21
  Stage, *n*:                        
   I/II                              15
   III/IV                            75
  Preoperative CEA levels \[U/ml\]   
   Mean (range )                     18.5 (0.2--279)
  Lymphovascular invasion, *n*:      
   Positive                          41
   Negative                          49
  Perineural invasion, *n*:          
   Positive                          40
   Negative                          50

MAC -- mucinous adenocarcinoma, SRC -- signet-ring cell carcinoma, CT -- chemotherapy, n -- number, CEA -- carcinoembryonic antigen.

Stage at diagnosis {#sec3.2}
------------------

Of the 90 patients, 75 (83.3%) presented with advanced-stage disease (stage III and IV). In particular, the proportion of distant metastasis was greater in the SRC group (38.0%) compared with the mucinous group (20%). The most common site of metastasis in the SRC group was peritoneum (*n* = 4, 50%), followed by liver (*n* = 2, 25%), while the common site of metastasis in MAC was liver (*n* = 7, 50%), followed by peritoneum (*n* = 4, 35.7%) ([Table II](#t0002){ref-type="table"}).

###### 

Initial metastatic sites at diagnosis

  Metastatic sites   MAC, *n* (%)                            SRC, *n* (%)
  ------------------ --------------------------------------- ------------------------------------
  Total              14[^\#^](#tf2-1){ref-type="table-fn"}   8[\*](#tf2-2){ref-type="table-fn"}
  Peritoneum         5                                       4
  Liver              7                                       1
  Lung               1                                       0
  Bone               1                                       1
  Lymph node         1                                       1
  Ovary              3                                       1

One MAC patient initially diagnosed with lymph node and liver metastasis; one MAC patients initially diagnosed with lung, liver, bone and peritoneum metastasis.

One SRC patient diagnosed with liver and lymph node metastasis; n -- number.

Pattern of failure {#sec3.3}
------------------

After a median follow-up of 36.5 months, the recurrence rate was significantly greater in the SRC group compared with the mucinous group (52.4% vs. 26.1%, χ^2^ = 3.96, *p* = 0.047). The specific sites of recurrence are listed in [Table III](#t0003){ref-type="table"}. The median DFS time for the SRC group was 17.0 ±11.2 months, which was significantly shorter than the MAC group 67.8 ±6.0 (*p* = 0.025).

###### 

Pattern of recurrence

  Stage              Recurrence sites   MAC, *n* (%)                            SRC, *n* (%)
  ------------------ ------------------ --------------------------------------- --------------
  I to III           Total              18[^\#^](#tf3-1){ref-type="table-fn"}   11
  Local recurrence   2                  5                                       
  Liver              4                  1                                       
  Lung               7                  1                                       
  Bone               1                  1                                       
  Lymph node         5                  3                                       
  Ovary              1                  0                                       
  Chest wall         1                  0                                       

One MAC patient relapsed with lymph node and chest wall metastasis; another MAC patient relapsed with liver, lung and bone metastasis; n -- number.

Treatment outcome {#sec3.4}
-----------------

The median overall survival (OS) for the whole series was 94 months. The overall cumulative 5-year OS rate was 56.6 ±6% ([Figure 1](#f0001){ref-type="fig"}). Estimated 5-year OS for MAC was significantly higher than SRC (58.1 ±7.7% vs. 31.3 ±12.9%, *p* = 0.018, [Figure 2](#f0002){ref-type="fig"}). The cumulative 5-year survival was 45.1% for women and 62.5% for men (*p* = 0.22). Additionally, estimated 5-year OS for early stage (stage I/II) CRC patients was also significantly higher than for late stage (stage III/IV) CRC patients (*p* = 0.024, [Figure 3](#f0003){ref-type="fig"}).

![Kaplan-Meier curves for overall survival in the young SRC and MAC patients](AMS-16-2-40001-g001){#f0001}

![Overall survival stratified by histologic subtypes in young patients](AMS-16-2-40001-g002){#f0002}

![Overall survival stratified by AJCC stages in young patients](AMS-16-2-40001-g003){#f0003}

Analysis of prognostic factors for overall survival {#sec3.5}
---------------------------------------------------

On univariate analysis, metastatic disease, AJCC stage, adjuvant chemotherapy (CT), cycles of adjuvant CT, surgery type, lymphovascular invasion, perineural invasion, preoperative CEA levels, and histologic type were significantly predictive for longer survival ([Table IV](#t0004){ref-type="table"}), whereas gender, tumor size and T stage were insignificant variables.

###### 

Predictive factors for overall survival by univariate and multivariate analyses of the cohort (*n* = 90)

  Factors                             Univariate analysis   Multivariate analysis                                  
  ----------------------------------- --------------------- ----------------------- ---------- ------ ------------ -------
  Gender:                                                                                                          
   Female                             1                                                        --                  
   Male                               0.67                  0.35--1.28              0.225      --     --           --
  Tumor location:                                                                                                  
   Rectum                             1                                                        1                   
   Colon                              0.55                  0.29--1.05              0.072      0.57   0.26--1.21   0.14
  Histologic types:                                                                                                
   MAC                                1                                                        1                   
   SRC                                2.28                  1.13--4.59              0.022      1.58   0.71--3.48   0.26
  Adjuvant CT:                                                                                                     
   No                                 1                                                        1                   
   Yes                                0.22                  0.088--0.53             0.001      1.29   0.27--6.19   0.75
  Cycles of adjuvant CT:                                                                                           
   \< 6                               1                                                        1                   
   ≥ 6                                0.29                  0.14--0.59              0.001      0.18   0.05--0.62   0.007
  Tumor size \[cm\]:                                                                                               
   \< 5                               1                                                        1                   
   ≥ 5                                1.89                  0.98--3.64              0.056      1.23   0.55--2.74   0.61
  Surgical types:                                                                                                  
   Radical                            1                                                        1                   
   Palliative                         4.41                  2.31--8.44              \< 0.001   1.40   0.37--5.28   0.62
  T stage:                                                                                                         
   T1/T2                              1                                                                            
   T3/T4                              2.70                  0.37--20.0              0.33       --                  
  N stage:                                                                                     --     --           --
   N0                                 1                                                        1                   
   N1/2                               2.65                  1.03--6.80              0.043      1.15   0.27--4.86   0.85
  Metastasis:                                                                                                      
   No                                 1                                                        1                   
   Yes                                5.15                  2.65--10.02             \< 0.001   1.83   0.50--6.64   0.36
  Stage:                                                                                                           
   I/II                               1                                                        1                   
   III/IV                             4.45                  1.07--18.5              0.04       1.84   0.26--12.9   0.54
  Preoperative CEA levels \[U/ml\]:                                                                                
   \< 5                               1                                                        1                   
   ≥ 5                                3.23                  1.69--6.17              \< 0.001   2.47   1.06--5.78   0.037
  Lymphovascular invasion:                                                                                         
   Negative                           1                                                        1                   
   Positive                           3.20                  1.62--6.29              0.001      1.36   0.53--3.47   0.52
  Perineural invasion:                                                                                             
   Negative                           1                                                        1                   
   Positive                           1.99                  1.04--3.81              0.038      1.38   0.53--3.60   0.50

HR -- hazard ratio, CI -- confidence interval, MAC -- mucinous adenocarcinoma, SRC -- signet-ring cell carcinoma, CT -- chemotherapy, CEA -- carcinoembryonic antigen.

In the Cox proportional hazard model, preoperative CEA levels (*p* = 0.037) and cycles of adjuvant CT (*p* = 0.007) were independent prognostic factors for overall survival ([Table IV](#t0004){ref-type="table"}).

Discussion {#sec4}
==========

Primary colorectal MAC and SRC are two rare subtypes of colorectal cancer with a worse prognosis than classic adenocarcinoma \[[@cit0015]--[@cit0017]\], but the prognosis and clinical features of MAC and SRC in young patients remain undetermined. Although CRC occurs predominantly in older patients, there is a small number of CRC patients who present at a younger age \[[@cit0018]\]. However, no agreement has been reached regarding the age cutoff for the diagnosis of colorectal cancer in young patients. In the present study, we used 40 years as a cut-off, which is based on previously published results \[[@cit0013], [@cit0014], [@cit0019], [@cit0020]\]. Our findings on gender differences are similar to all the published reports on colorectal cancer under age 40, with the male-to-female ratio of 2.1 : 1. On the other hand, in this study male patients had a better outcome than female patients, but the difference was not significant (*p* = 0.22). Another important finding of this study is that young MAC and SRC patients presented with advanced-stage disease. Berut *et al.* \[[@cit0003]\] reported that CRC in young patients was often diagnosed in advanced stages. Nitsche *et al.* \[[@cit0016]\] also found that MAC and SRC patients had higher stages of the primary tumor and lymph node involvement. Consistently with previous results, 75 (83.3%) of 90 patients presented with stage III and IV disease. Peritoneal dissemination is a common metastatic site of CRC, which is present in approximately 7% of CRC patients at the time of diagnosis \[[@cit0021]\]. Several risk factors for the development of peritoneal metastases have been identified, including right-sided tumor, advanced T-stage, advanced N-stage, poor differentiation grade, and younger age at diagnosis \[[@cit0022]\]. In concordance with the literature, our study showed that the peritoneum is the most common site of metastasis in young patients with SRC and MAC.

Most published studies suggest that MAC and SRC are associated with poor outcomes. Messerini *et al.* \[[@cit0023]\] reported that the overall 5-year survival rate of those with SRC of the colorectum was 9.1%, and survival was influenced significantly by tumor stage. Nitsche *et al.* \[[@cit0016]\] found that 5-year cause-specific survival was 61 ±3% for MAC and 21 ±8% for SRC. Chen *et al.* \[[@cit0017]\] also reported that the 5-year overall survival rates of patients with SRC and MAC were 11.9% and 49.4%, respectively. Lee *et al.* \[[@cit0024]\] reported that 3- and 5-year survival rates in the SRC group were 33.7% and 25.3%, respectively. The overall survival rate of patients with SRC was significantly poorer than that of patients with mucinous or poorly differentiated adenocarcinoma. The findings of the present study are consistent with these published reports. Based on these findings, SRC patients could be regarded as a different clinical entity due to its poor prognosis \[[@cit0016]\]. Indeed, carcinogenetic factors, tumor growth, and development have been described to be different in SRC than in non-SRC tumors \[[@cit0025]\]. Additionally, we conducted a multivariate regression analysis and found a survival advantage for patients presenting with normal preoperative CEA levels and those who received more than six cycles of adjuvant CT. Based on our findings, sufficient cycles of adjuvant CT are recommended for young MAC and SRC patients with high risk factors.

Distant failure has been the predominant failure pattern after the routine use of surgery and adjuvant chemotherapy in patients with locally advanced CRC patients. In our series, distant metastasis is the most common type of failure in MAC patients, seen in 16 patients. The lung, liver and lymph nodes have been the most common sites of distant recurrence in patients with MAC. Interestingly, local recurrence is the most common type of failure in SRC patients, seen in 5 patients. The lymph nodes are the most common sites of distant recurrence in patients with SRC. This findings of the present study are consistent with previous results. Lee *et al*. \[[@cit0026]\] reported that recurrence after resection in the SRC group was significantly higher than that of the non-mucinous adenocarcinoma group (33.3% vs. 10.7%, *p* = 0.038).

The current study is limited by its retrospective design, the relatively small number of young SRC and MAC patients and possible patient selection bias. However, it appears difficult to conduct a randomized trial for this rare disease in young patients. In addition, this is the first study, to our best knowledge, specifically assessing the long-term survival and prognostic factors of young patients with SRC and MAC.

In conclusion, a greater proportion of young patients with MAC and SRC present with advanced disease. Young patients with SRC have poorer prognosis than MAC. The most common type of failure in young SRC is local recurrence, while it is lung metastasis for MAC. Preoperative CEA levels and cycles of adjuvant CT are two independent predictors of overall survival for young CRC patients with MAC and SRC.
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